Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 25, 485–486 (1 May 2007) | doi:10.1038/nbt0507-485
Critics pan timid European response to TeGenero disaster
Abstract
Proposals unlikely to remove the cloud surrounding first-in-human trials of many novel biologics
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
